Printer Friendly

MARION MERRELL DOW FILES SUIT OVER COMPETITOR'S CLAIMS THAT DRUGS ARE SIMILAR

 KANSAS CITY, Mo., Feb. 12 /PRNewswire/ -- Marion Merrell Dow Inc. (NYSE: MKC) filed a lawsuit today against Rhone-Poulenc Rorer (RPR) alleging that RPR is distributing false and misleading promotional materials to physicians and pharmacists. Those materials claim that RPR's antihypertensive product, Dilacor XR(R), shows similar bioavailability to Marion Merrell Dow's Cardizem(R) CD.
 In fact, recent scientific studies show that there is a significant difference in bioavailability, which is the rate and extent of absorption of a drug into a patient's bloodstream. For example, data indicate that a 180-milligram Dilacor XR capsule delivers only about 80 percent of the active ingredient that is delivered by a 180-milligram Cardizem CD capsule. Based on the scientific data, Marion Merrell Dow's suit alleges that promotional attempts to compare RPR's product with Cardizem CD are misleading and false.
 Cardizem CD is a 24-hour capsule for treatment of hypertension (high blood pressure) and angina (chest pain due to insufficient blood flow to the heart). More than five million prescriptions for Cardizem CD have been filled in the United States since the product was introduced at the end of 1991.
 Unlike a generic equivalent, RPR's product cannot be substituted by a pharmacist for Cardizem CD. There is no generic equivalent for Cardizem CD. Also, Dilacor XR is not approved for the treatment of angina.
 Marion Merrell Dow is a research-based global pharmaceutical organization dedicated to improving the longevity and quality of human life. The company is involved in the discovery, development, manufacture and sale of pharmaceutical products worldwide. In 1992, Marion Merrell Dow had sales of $3.3 billion and invested $465 million in Research and Development.
 -0- 2/12/93
 /CONTACT: David M. Thompson or Richard M. Johnson of Marion Merrell Dow, 816-966-4000/
 (MKC)


CO: Marion Merrell Dow Inc. ST: Missouri IN: MTC SU:

BB -- DV008 -- 6363 02/12/93 18:52 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 12, 1993
Words:309
Previous Article:OVER 70 U.S. VIDEO GAME COMPANIES CHARGE TAIWAN WITH COPYRIGHT AND TRADEMARK PIRACY
Next Article:U.S. SUGAR IMPLEMENTS ON FARM PHOSPHORUS REDUCTION PROGRAM AS ALTERNATIVE TO PROPOSED STORM WATER TREATMENT SYSTEM
Topics:


Related Articles
MARION MERRELL DOW ANNOUNCES SETTLEMENT WITH GENERIC MAKER ON LOOK-ALIKE TABLETS
ALZA, CYANAMID, ELAN AND MARION MERRELL CONCLUDE AGREEMENTS AND REACH AN OUT-OF-COURT SETTLEMENT
MARION MERRELL DOW AND RHONE-POULENC RORER REACH AGREEMENT TO SETTLE DISPUTES REGARDING ANTIHYPERTENSIVE DRUGS
MARION MERRELL DOW & TANABE SEIYAKU
RHONE-POULENC RORER FILES LAWSUIT AGAINST MARION MERRELL DOW ALLEGING FALSE AND MISLEADING PROMOTION
RHONE-POULENC RORER FILES FOR PELIMINARY INJUNCTION AGAINST MARION MERRELL DOW, ALLEGING FALSE AND MISLEADING PROMOTION
MARION MERRELL DOW AND TANABE SEIYAKU FILE INTERNATIONAL TRADE COMPLAINT AGAINST CARDIZEM IMITATORS
MARION MERRELL DOW COMMENTS ON COURT CASE
MARION MERRELL DOW INC. FILES LAWSUIT OVER PATENT INFRINGEMENT
COURT RULES IN FAVOR OF ALZA & MARION MERRELL DOW, DECLARES CIBA-GEIGY NICOTINE PATENT INVALID

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters